SPX3,647.29-7.75 -0.21%
DIA291.30-1.42 -0.49%
IXIC10,829.50+26.58 0.25%

Portage Biotech Provides Research And Development Update; Highlights Its Clinical Strategy For Its Adenosine And iNKT Platforms; Development Goals Are Focused On Producing Phase 1b/Phase 2 Efficacy Readouts In Multiple Tumor Types Over The Next Two Years

--The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms--   --Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types Over the Next

Benzinga · 09/14/2022 08:42

--The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms--
 

--Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types Over the Next two Years--

WESTPORT, Conn., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today provided an update on its research and development programs for its expanded portfolio of immuno-oncology assets, and outlined its forward-looking clinical development goals for the next two years.

"Following the transactions we executed over this past summer, we are focusing our research and development priorities on 1) converting our investigator-initiated PORT-2 study into a company-sponsored study and 2) launching our company-sponsored adenosine trial (PORT-6 and PORT-7) in the U.S.," said Dr. Ian Walters, Chief Executive Officer and Chairman of Portage. "The reception from major academic centers and thought leaders for both of these trials, now named IMPORT and ADPORT, respectively, has been positive. Given the potential for broad immune targeting, both trials and all agents are being tested as single agents as well as in combination with other drugs. These trials are also designed to potentially enrich for patients that may be more likely to respond to treatment, including patients with high expression of adenosine receptors A2A and A2B. Utilizing our adaptive drug development strategy, we are confident that we can continue to build on our fundamental understanding of immuno-oncology treatments and deliver on multiple catalysts within our current cash runway, which potentially extends into 2024."